In a new article,

The scientific community and HIV/AIDS activists are abuzz about the preliminary findings of a new PrEP study showing not only the effectiveness of the treatment overall, but the success of an innovative regimen wherein participants took PrEP only when they anticipated having sex instead of taking it daily as it is currently prescribed.

Participants in the IPERGAY trial, which occurred in France and Canada and closed early due to high effectiveness, took two pills of Truvada in the 24-hour period before anticipated sex and, if sex occurred, then took two separate one-pill doses of the drug in the two days following sex. IPERGAY investigators did not release any effectiveness figures or other data, but will do so once a complete analysis of the results has been completed, which they say should be sometime in early 2015.

Read the whole piece  at  GA VOICE

Travada Financial Assistance  information